Bioequivalence Study of 75 mg Clopidogrel Film Coated Tablets Produced by PT. Novell Pharmaceutical Laboratories in Comparison with Plavix® 75 mg Film Coated Tablets Manufactured by Sanofi Winthrop Industrie, France

Tahapan Penelitian : Complete
Sponsor:
Mitra Pelaksana:
PT Clinisindo Laboratories
No Registry
INA-P8T343X
Tanggal Input Registry : 15-06-2023

11-01-2019
AUC0-t , AUC0-inf , Cmax
Tmax, t1/2
 
Bioequivalence Study of 75 mg Clopidogrel Film Coated Tablets Produced by PT. Novell Pharmaceutical Laboratories in Comparison with Plavix® 75 mg Film Coated Tablets Manufactured by Sanofi Winthrop Industrie, France
Bioequivalence Study of 75 mg Clopidogrel Film Coated Tablets Produced by PT. Novell Pharmaceutical Laboratories in Comparison with Plavix® 75 mg Film Coated Tablets Manufactured by Sanofi Winthrop Industrie, France
Interventional
Clopidogrel 75 mg Tablet manufactured by PT Novell Pharmaceutical Laboratories
30
 

Inclusion Criteria:

1. Healthy subjects, both sexes, age between 18 to 55 years old 2. Weight with the normal range according to accepted normal values for the Body Mass Index (BMI = 18-25 kg/m2 3. Accepted normal values of blood pressure (systolic blood pressure 90 mmHg, diastolic blood pressure 60 mmHg) and heart rate (60-90 bpm) 4. Gave written informed consent 5. Acceptable medical history and physical examination 6. Normal hematology values including: hemoglobin, hematocrit, erythrocyte, leukocyte, mean corpuscular (MC) values, leukocyte differential, platelets count and erythrocyte sedimentation rate (ESR).* 7. Normal laboratory tests including: sGPT, sGOT, alkaline phosphatase, total bilirubin, total protein, albumin, globulin, fasting glucose, total cholesterol, blood urea nitrogen, ureum, creatinine.* 8. Normal urinalysis results including: color, clarity, specific gravity, pH, leukocyte esterase, nitrite, glucose, keton, urobilinogen, bilirubin, blood and urine sediments (cells, casts, and bacteria).* 9. Acceptable electrocardiogram (ECG) result. Initial ECG would be required from subjects who have never participated in BA/BE study at Clinisindo. ECG would be required every six months from subjects who have previously participated in a BA/BE study at Clinisindo. 10. Negative result for serological tests of hepatitis B antigen (HBsAg), Hepatitis C (anti HCV), HIV (anti HIV) 11. Negative result for drug of abuse tests of amphetamine, metamphetamine, morphine, marijuana/tetrahydrocannabinol (THC), and benzodiazepine. 12. Negative result for pregnancy test (would be done for female subjects at screening, before period I and before period II of the study) Note: * The clinical investigator might include a subject having value outside the accepted range, if in his/her opinion, these values were not clinically significant.

Exclusion Criteria:

1. Smoker. If necessary, light smoker (≤5 cigarettes/day) could be accepted. 2. Pregnant woman or nursing mother. 3. Had history of hepatic, cardiovascular, gastrointestinal or renal disease 4. Potentially hypersensitive to clopidogrel.(3,4) 5. Had severe hepatic impairment.(3,4) 6. Had an active pathological bleeding such as peptic ulcer or intracranial haemorrhage.(3,4) 7. History of alcohol, drug abuse within 12 months prior to screening for this study. 8. Received any other medications within fourteen days prior to the start of the study. 9. Participated in any clinical study within 3 months after the date of completion. 10. Donation or loss more than 450 mL of blood within 3 months prior to the screening of the study.
 
1069/UN2.F1/ETIK/2017
Not applicable
PPUK/PPUB number
Apt. Windy Lusthom, S.Si – Study Director Telp : (62-21) 73889918, e-Mail: Windy.Lusthom@clinisindo.com